$15.83
Today
as of Jul 22, 16:47 ET
Last 30 days
Recent Press Releases & News
Crescent Biopharma Closes $143.7 Million Public Offering
Crescent Biopharma Announces Closing of Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Crescent Biopharma Prices $125 Million Common, Warrant Offering
Overview
52-week range
$8.72
$27
38% of range
Avg surprise (last 1)
-83.3%
Avg reaction (last 1)
-4.0%
0% positive
Latest IV / EM
152%
EM ±34.7% · $15 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Thu Jul 31, 2025 | Jun/2025 | $-4.93 | $-2.69 | -83.3% | — | — | earnings |
| Wed May 14, 2025 | Mar/2025 | $-0.04 | — | — | — | -4.0% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.15 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.16 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.04 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.14 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.13 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Thu Jul 30, 2026 | Jun/2026 | OTHER | -$0.78 | -$4.93 | +84.2% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-25M | — | $-26M | $-21M | $-14M | — | $-11M | $-10M |
| Net income | $-23M | $-23M | $-25M | $-22M | $-15M | — | $-10M | $-10M |
| EPS (diluted) | — | — | — | — | — | — | $-0.15 | $-0.16 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $189M | $213M | $133M | — | $22M | $35M | $14M | $22M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $196M | $237M | $135M | $154M | $6M | $35M | $16M | $24M |
| Total assets | $199M | $240M | $138M | $157M | $6M | $36M | $16M | $24M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $15M | $37M | $22M | $18M | $3M | $47M | $4M | $4M |
| Total equity | $184M | $203M | $117M | $139M | $-30M | $-15M | $-1M | $20M |